{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:09:42Z","timestamp":1762430982754,"version":"3.37.3"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2015,5,20]],"date-time":"2015-05-20T00:00:00Z","timestamp":1432080000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001826","name":"Netherlands Organisation for Health Research and Development","doi-asserted-by":"publisher","award":["43400003","VIDI-917.11.337"],"award-info":[{"award-number":["43400003","VIDI-917.11.337"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"name":"WorldWideCancerResearch","award":["10-736","15-0049","VIDI-917.11.337"],"award-info":[{"award-number":["10-736","15-0049","VIDI-917.11.337"]}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["UU-2010-4669","UU-2013-6426","UU 2014-6790"],"award-info":[{"award-number":["UU-2010-4669","UU-2013-6426","UU 2014-6790"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["UU 2015-7553"],"award-info":[{"award-number":["UU 2015-7553"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1007\/s00262-015-1710-8","type":"journal-article","created":{"date-parts":[[2015,5,19]],"date-time":"2015-05-19T11:07:50Z","timestamp":1432033670000},"page":"893-902","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Orchestrating an immune response against cancer with engineered immune cells expressing \u03b1\u03b2TCRs, CARs, and innate immune receptors: an immunological and regulatory challenge"],"prefix":"10.1007","volume":"64","author":[{"given":"Moniek A.","family":"de Witte","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido J. J.","family":"Kierkels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trudy","family":"Straetemans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cedrik M.","family":"Britten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Kuball","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,5,20]]},"reference":[{"key":"1710_CR1","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1056\/NEJM200009143431101","volume":"343","author":"R Childs","year":"2000","unstructured":"Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S et al (2000) Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 343:750\u2013758","journal-title":"N Engl J Med"},{"key":"1710_CR2","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nri3191","volume":"12","author":"NP Restifo","year":"2012","unstructured":"Restifo NP, Dudley ME, Rosenberg SA (2012) Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 12:269\u2013281","journal-title":"Nat Rev Immunol"},{"key":"1710_CR3","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","volume":"371","author":"A Snyder","year":"2014","unstructured":"Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A et al (2014) Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 371:2189\u20132199","journal-title":"N Engl J Med"},{"key":"1710_CR4","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","volume":"364","author":"C Robert","year":"2011","unstructured":"Robert C, Thomas L, Bondarenko I, O\u2019Day S, Weber J, Garbe C et al (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:2517\u20132526","journal-title":"N Engl J Med"},{"key":"1710_CR5","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1089\/hum.2010.086","volume":"21","author":"R. E. Hawkins, D. E. Gilham, R. Debets, Z. Eshhar, N. Taylor, H. Abken, T. N. Schumacher, and ATTACK Consortium","year":"2010","unstructured":"R. E. Hawkins, D. E. Gilham, R. Debets, Z. Eshhar, N. Taylor, H. Abken, T. N. Schumacher, and ATTACK Consortium (2010) Development of adoptive cell therapy for cancer: a clinical perspective. Hum Gene Ther 21:665\u2013672","journal-title":"Hum Gene Ther"},{"key":"1710_CR6","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.4049\/jimmunol.181.7.5128","volume":"181","author":"MA Witte de","year":"2008","unstructured":"de Witte MA, Jorritsma A, Kaiser A, van den Boom MD, Dokter M, Bendle GM et al (2008) Requirements for effective antitumor responses of TCR transduced T cells. J Immunol 181:5128\u20135136","journal-title":"J Immunol"},{"key":"1710_CR7","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1182\/blood-2013-09-529537","volume":"123","author":"S Gill","year":"2014","unstructured":"Gill S, Tasian SK, Ruella M, Shestova O, Li Y, Porter DL et al (2014) Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. Blood 123:2343\u20132354","journal-title":"Blood"},{"key":"1710_CR8","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1126\/science.1129003","volume":"314","author":"R Morgan","year":"2006","unstructured":"Morgan R, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM et al (2006) Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314:126\u2013129","journal-title":"Science"},{"key":"1710_CR9","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","volume":"365","author":"DL Porter","year":"2011","unstructured":"Porter DL, Levine BL, Kalos M, Bagg A, June CH (2011) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365:725\u2013733","journal-title":"N Engl J Med"},{"key":"1710_CR10","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/leu.2013.378","volume":"28","author":"W Scheper","year":"2013","unstructured":"Scheper W, Gr\u00fcnder C, Straetemans T, Sebestyen Z, Kuball J (2013) Hunting for clinical translation with innate-like immune cells and their receptors. Leukemia 28:1181\u20131190","journal-title":"Leukemia"},{"key":"1710_CR11","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/imr.12130","volume":"257","author":"N Cieri","year":"2014","unstructured":"Cieri N, Mastaglio S, Oliveira G, Casucci M, Bondanza A, Bonini C (2014) Adoptive immunotherapy with genetically modified lymphocytes in allogeneic stem cell transplantation. Immunol Rev 257:165\u2013180","journal-title":"Immunol Rev"},{"key":"1710_CR12","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/bmt.2013.204","volume":"49","author":"F Baron","year":"2014","unstructured":"Baron F, Labopin M, Blaise D, Lopez-Corral L, Vigouroux S, Craddock C et al (2014) Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor: a report from the Acute Leukemia working party of the European group for blood and bone marrow transplantation. Bone Marrow Transplant 49:389\u2013396","journal-title":"Bone Marrow Transplant"},{"key":"1710_CR13","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2012.41.7071","volume":"30","author":"MC Pasquini","year":"2012","unstructured":"Pasquini MC, Devine S, Mendizabal A, Baden LR, Wingard JR, Lazarus HM et al (2012) Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transpl. J Clin Oncol 30:3194\u20133201","journal-title":"J Clin Oncol"},{"key":"1710_CR14","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1097\/MOH.0b013e3283582340","volume":"19","author":"R Handgretinger","year":"2012","unstructured":"Handgretinger R (2012) Negative depletion of CD3(+) and TcR\u03b1\u03b2(+) T cells. Curr Opin Hematol 19:434\u2013439","journal-title":"Curr Opin Hematol"},{"key":"1710_CR15","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1182\/blood-2014-03-563817","volume":"124","author":"A Bertaina","year":"2014","unstructured":"Bertaina A, Merli P, Rutella S, Pagliara D, Bernardo ME, Masetti R et al (2014) HLA-haploidentical stem cell transplantation after removal of ab\u2014T and B cells in children with nonmalignant disorders. Blood 124:822\u2013826","journal-title":"Blood"},{"key":"1710_CR16","doi-asserted-by":"crossref","first-page":"601","DOI":"10.3389\/fimmu.2014.00601","volume":"5","author":"W Scheper","year":"2014","unstructured":"Scheper W, Sebestyen Z, Kuball J (2014) Cancer immunotherapy using \u03b3\u03b4T cells: dealing with diversity. Front Immunol 5:601","journal-title":"Front Immunol"},{"key":"1710_CR17","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1182\/blood-2004-10-4113","volume":"105","author":"S Nguyen","year":"2005","unstructured":"Nguyen S, Dhedin N, Vernant J-P, Kuentz M, Al Jijakli A, Rouas-Freiss N et al (2005) NK-cell reconstitution after haploidentical hematopoietic stem-cell transplantations: immaturity of NK cells and inhibitory effect of NKG2A override GvL effect. Blood 105:4135\u20134142","journal-title":"Blood"},{"key":"1710_CR18","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1182\/blood.V87.6.2195.bloodjournal8762195","volume":"87","author":"S Slavin","year":"1996","unstructured":"Slavin S, Naparstek E, Nagler A, Ackerstein A, Samuel S, Kapelushnik J, Brautbar C, Or R (1996) Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 87:2195\u20132204","journal-title":"Blood"},{"key":"1710_CR19","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1182\/blood.V86.5.2041.bloodjournal8652041","volume":"86","author":"HJ Kolb","year":"1995","unstructured":"Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W et al (1995) Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86:2041\u20132050","journal-title":"Blood"},{"key":"1710_CR20","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1200\/JCO.2000.18.16.3031","volume":"18","author":"HM Lokhorst","year":"2000","unstructured":"Lokhorst HM, Schattenberg A, Cornelissen JJ, van Oers MH, Fibbe W, Russell I et al (2000) Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. J Clin Oncol 18:3031\u20133037","journal-title":"J Clin Oncol"},{"key":"1710_CR21","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/bmt.2013.111","volume":"49","author":"M Eefting","year":"2014","unstructured":"Eefting M, Halkes CJM, de Wreede LC, van Pelt CM, Kersting S, Marijt EWA et al (2014) Myeloablative T cell-depleted alloSCT with early sequential prophylactic donor lymphocyte infusion is an efficient and safe post-remission treatment for adult ALL. Bone Marrow Transplant 49:287\u2013291","journal-title":"Bone Marrow Transplant"},{"key":"1710_CR22","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1038\/ni1001-957","volume":"2","author":"HW Kessels","year":"2001","unstructured":"Kessels HW, Wolkers MC, van den Boom MD, van der Valk MA, Schumacher TN (2001) Immunotherapy through TCR gene transfer. Nat Immunol 2:957\u2013961","journal-title":"Nat Immunol"},{"key":"1710_CR23","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3389\/fimmu.2013.00363","volume":"4","author":"A Kunert","year":"2013","unstructured":"Kunert A, Straetemans T, Govers C, Lamers C, Mathijssen R, Sleijfer S, Debets R (2013) TCR-engineered T cells meet new challenges to treat solid tumors: choice of antigen, T cell fitness, and sensitization of tumor Milieu. Front Immunol 4:363","journal-title":"Front Immunol"},{"key":"1710_CR24","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nature10755","volume":"482","author":"H Matsushita","year":"2012","unstructured":"Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, Arthur CD et al (2012) Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 482:400\u2013404","journal-title":"Nature"},{"key":"1710_CR25","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/nm.3161","volume":"19","author":"PF Robbins","year":"2013","unstructured":"Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J et al (2013) Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med 19:747\u2013752","journal-title":"Nat Med"},{"key":"1710_CR26","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","volume":"368","author":"S Grupp","year":"2013","unstructured":"Grupp S, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR et al (2013) Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368:1509\u20131518","journal-title":"N Engl J Med"},{"key":"1710_CR27","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1182\/blood-2013-11-492231","volume":"123","author":"MV Maus","year":"2014","unstructured":"Maus MV, Grupp S, Porter DL, June CH (2014) Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood 123:2625\u20132635","journal-title":"Blood"},{"key":"1710_CR28","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S1471-4906(01)02060-9","volume":"22","author":"MA Cooper","year":"2001","unstructured":"Cooper MA, Fehniger TA, Caligiuri MA (2001) The biology of human natural killer-cell subsets. Trends Immunol 22:633\u2013640","journal-title":"Trends Immunol"},{"key":"1710_CR29","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1126\/science.285.5428.727","volume":"285","author":"S Bauer","year":"1999","unstructured":"Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, Spies T (1999) Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285:727\u2013729","journal-title":"Science"},{"key":"1710_CR30","first-page":"8","volume":"13","author":"P Spear","year":"2013","unstructured":"Spear P, Wu MR, Sentman ML, Sentman CL (2013) NKG2D ligands as therapeutic targets. Cancer Immun 13:8","journal-title":"Cancer Immun"},{"key":"1710_CR31","doi-asserted-by":"crossref","first-page":"e2150","DOI":"10.1371\/journal.pone.0002150","volume":"3","author":"TI Arnon","year":"2008","unstructured":"Arnon TI, Markel G, Bar-Ilan A, Hanna J, Fima E, Benchetrit F et al (2008) Harnessing soluble NK cell killer receptors for the generation of novel cancer immune therapy. PLoS ONE 3:e2150","journal-title":"PLoS ONE"},{"key":"1710_CR32","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1084\/jem.176.4.963","volume":"176","author":"E Ciccone","year":"1992","unstructured":"Ciccone E, Pende D, Viale O, Than A, Di Donato C, Orengo AM et al (1992) Involvement of HLA class I alleles in natural killer (NK) cell-specific functions: expression of HLA-Cw3 confers selective protection from lysis by alloreactive NK clones displaying a defined specificity (specificity 2). J Exp Med 176:963\u2013971","journal-title":"J Exp Med"},{"key":"1710_CR33","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1182\/blood-2012-06-437558","volume":"120","author":"N Vey","year":"2012","unstructured":"Vey N, Bourhis JH, Boissel N, Bordessoule D, Prebet T, Charbonnier A et al (2012) A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission. Blood 120:4317\u20134323","journal-title":"Blood"},{"key":"1710_CR34","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1158\/0008-5472.CAN-10-3200","volume":"71","author":"T Zhang","year":"2011","unstructured":"Zhang T, Sentman CL (2011) Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells. Cancer Res 71:2066\u20132076","journal-title":"Cancer Res"},{"key":"1710_CR35","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.4049\/jimmunol.0903454","volume":"184","author":"M D\u2019Asaro","year":"2010","unstructured":"D\u2019Asaro M, La Mendola C, Di Liberto D, Orlando V, Todaro M, Spina M et al (2010) V gamma 9\u00a0V delta 2 T lymphocytes efficiently recognize and kill zoledronate-sensitized, imatinib-sensitive, and imatinib-resistant chronic myelogenous leukemia cells. J Immunol 184:3260\u20133268","journal-title":"J Immunol"},{"key":"1710_CR36","doi-asserted-by":"crossref","first-page":"7287","DOI":"10.4049\/jimmunol.0804288","volume":"182","author":"M Todaro","year":"2009","unstructured":"Todaro M, D\u2019Asaro M, Caccamo N, Iovino F, Francipane MG, Meraviglia S et al (2009) Efficient killing of human colon cancer stem cells by gammadelta T lymphocytes. J Immunol 182:7287\u20137296","journal-title":"J Immunol"},{"key":"1710_CR37","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.ccr.2014.07.026","volume":"26","author":"Z Xiang","year":"2014","unstructured":"Xiang Z, Liu Y, Zheng J, Liu M, Lv A, Gao Y et al (2014) Targeted activation of human V\u03b39\u00a0V\u03b42-T cells controls epstein-barr virus-induced B cell lymphoproliferative disease. Cancer Cell 26:565\u2013576","journal-title":"Cancer Cell"},{"key":"1710_CR38","doi-asserted-by":"crossref","first-page":"5153","DOI":"10.1182\/blood-2012-05-432427","volume":"120","author":"C Gr\u00fcnder","year":"2012","unstructured":"Gr\u00fcnder C, van Dorp S, Hol S, Drent E, Straetemans T, Heijhuurs S et al (2012) \u03b39 and \u03b42CDR3 domains regulate functional avidity of T cells harboring \u03b39\u03b42TCRs. Blood 120:5153\u20135162","journal-title":"Blood"},{"key":"1710_CR39","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.smim.2010.04.004","volume":"22","author":"S Nedellec","year":"2010","unstructured":"Nedellec S, Bonneville M, Scotet E (2010) Human Vgamma9Vdelta2 T cells: from signals to functions. Semin Immunol 22:199\u2013206","journal-title":"Semin Immunol"},{"key":"1710_CR40","doi-asserted-by":"crossref","first-page":"9190","DOI":"10.1073\/pnas.0603503103","volume":"103","author":"M Jinushi","year":"2006","unstructured":"Jinushi M, Hodi FS, Dranoff G (2006) Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity. Proc Natl Acad Sci USA 103:9190\u20139195","journal-title":"Proc Natl Acad Sci USA"},{"key":"1710_CR41","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1182\/blood-2010-12-325993","volume":"118","author":"V Marcu-Malina","year":"2011","unstructured":"Marcu-Malina V, Heijhuurs S, van Buuren M, Hartkamp L, Strand S, Sebestyen Z et al (2011) Redirecting \u03b1\u03b2 T cells against cancer cells by transfer of a broadly tumor-reactive \u03b3\u03b4T-cell receptor. Blood 118:50\u201359","journal-title":"Blood"},{"key":"1710_CR42","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.tibtech.2011.04.009","volume":"29","author":"TS Park","year":"2011","unstructured":"Park TS, Rosenberg SA, Morgan RA (2011) Treating cancer with genetically engineered T cells. Trends Biotechnol 29:550\u2013557","journal-title":"Trends Biotechnol"},{"key":"1710_CR43","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3389\/fimmu.2013.00244","volume":"4","author":"JD Stone","year":"2013","unstructured":"Stone JD, Kranz DM (2013) Role of T cell receptor affinity in the efficacy and specificity of adoptive T cell therapies. Front Immunol 4:244","journal-title":"Front Immunol"},{"key":"1710_CR44","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1126\/scitranslmed.3006034","volume":"5","author":"BJ Cameron","year":"2013","unstructured":"Cameron BJ, Gerry AB, Dukes J, Harper JV, Kannan V, Bianchi FC et al (2013) Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci Transl Med 5:197","journal-title":"Sci Transl Med"},{"key":"1710_CR45","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/mt.2011.288","volume":"20","author":"AS Bear","year":"2012","unstructured":"Bear AS, Morgan RA, Cornetta K, June CH, Binder-Scholl G, Dudley ME et al (2012) Replication-competent retroviruses in gene-modified T cells used in clinical trials: is it time to revise the testing requirements? Mol Ther 20:246\u2013249","journal-title":"Mol Ther"},{"key":"1710_CR46","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1126\/scitranslmed.3003761","volume":"4","author":"J Scholler","year":"2012","unstructured":"Scholler J, Brady TL, Binder-Scholl G, Hwang W-T, Plesa G, Hege KM et al (2012) Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med 4:132","journal-title":"Sci Transl Med"},{"key":"1710_CR47","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/nbt.2708","volume":"31","author":"CM Britten","year":"2013","unstructured":"Britten CM, Singh-Jasuja H, Flamion B, Hoos A, Huber C, Kallen K-J et al (2013) The regulatory landscape for actively personalized cancer immunotherapies. Nat Biotechnol 31:880\u2013882","journal-title":"Nat Biotechnol"},{"key":"1710_CR48","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1089\/hum.2014.017","volume":"25","author":"D Gancberg","year":"2014","unstructured":"Gancberg D, Draghia-Akli R (2014) Gene and cell therapy funding opportunities in horizon 2020: an overview for 2014\u20132015. Hum Gene Ther 25:175\u2013177","journal-title":"Hum Gene Ther"},{"key":"1710_CR49","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/S0140-6736(12)60430-9","volume":"379","author":"MJH Kenter","year":"2012","unstructured":"Kenter MJH, Cohen AF (2012) Re-engineering the European union clinical trials directive. Lancet 379:1765\u20131767","journal-title":"Lancet"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-015-1710-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-015-1710-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-015-1710-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T10:10:20Z","timestamp":1599041420000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-015-1710-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,20]]},"references-count":49,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["1710"],"URL":"https:\/\/doi.org\/10.1007\/s00262-015-1710-8","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"type":"print","value":"0340-7004"},{"type":"electronic","value":"1432-0851"}],"subject":[],"published":{"date-parts":[[2015,5,20]]}}}